Route 92 Medical, Inc.

Based in the US, Route 92 Medical, Inc. specializes in advanced neurovascular intervention products, focusing on improving outcomes for stroke treatments and related therapies. Route 92 Medical, Inc. was founded in 2015 and is headquartered in San Mateo, US.

The company develops innovative neurovascular intervention systems and has successfully completed a total of 8 funding deals. The most recent funding occurred on September 23, 2024, when the company raised USD 82 mn in a Series F round from investors, including Novo Holdings, US Venture Partners, Vertical Group, InnovaHealth Partners, and Norwest Venture Partners. The company's current valuation is USD 202. 31 mn.

Tony Chou serves as both the Founder and CEO. Route 92 Medical focuses on enhancing neurovascular intervention outcomes through its advanced product offerings. Their core products include the FreeClimb catheter systems—FreeClimb 54, FreeClimb 70, and FreeClimb 88—which are specifically engineered to navigate challenging anatomical structures, allowing for efficient delivery of neurointerventional therapies. The company is also developing the Monopoint Reperfusion System, currently undergoing evaluation in the SUMMIT MAX clinical trial, which aims to streamline delivery and improve aspiration in treating strokes.

These products primarily target hospitals and healthcare facilities within the United States, with potential expansion into international markets as they gain regulatory approvals. Revenue generation for Route 92 Medical is expected to stem from direct sales of its advanced neurointervention systems to hospitals and healthcare providers. The company's flagship products, including the FreeClimb catheter systems and the Monopoint Reperfusion System, are sold as individual units or in bundles, catering to the specific needs of healthcare facilities. Transactions may involve direct sales agreements, where healthcare providers procure devices based on procedural requirements, as well as collaborations with medical distributors to enhance market reach.

By focusing on high-value contracts with hospitals and leveraging clinical evidence from trials, Route 92 Medical aims to establish a steady revenue stream as it expands its presence in the neurovascular market. In September 2024, Route 92 Medical, Inc. raised USD 82 mn in Series F funding to support global commercial expansion. The company plans to launch the Monopoint Reperfusion System and is targeting new markets, including specific international healthcare facilities, as regulatory approvals are obtained.

The recent funding will facilitate these initiatives, enhancing their capabilities in the neurovascular device sector.